Table 2. The XRCC3 Thr241Met polymorphism and response to platinum-based chemotherapy.

		Allele Comparison			Homozygote Comparison			Heterozygote Comparison			Recessive Model			Dominant Model
	Num	OR(95% CI)	P	Num	OR(95% CI)	P	Num	OR(95% CI)	P	Num	OR(95% CI)	P	Num	OR(95% CI)	P
Overall	5	1.453 (1.116–1.892)*	0.968	3	1.983 (1.092–3.599)*	0.868	5	1.744 (1.169–2.601)*	0.527	3	1.390 (0.839–2.303)	0.343	8	1.476 (1.087–2.004)*	0.696
Ethnicity
Asian	2	1.871 (0.738–4.748)	0.66	NA	NA	NA	2	1.953 (0.745–5.120)	0.638	NA	NA	NA	5	1.179 (0.745–1.866)	0.776
Caucasian	2	1.421 (1.028–1.964)*	0.828	2	2.148 (1.073–4.298)*	0.78	2	1.349 (0.807–2.254)	0.875	2	1.751 (0.967–3.172)	0.695	2	1.509 (0.928–2.455)	0.803
Mixed	1	1.428 (0.849–2.403)	NA	1	1.569 (0.483–5.098)	NA	1	3.243 (1.349–7.795)*	NA	1	0.755 (0.275–2.075)	NA	1	2.716 (1.169–6.309)*	NA

Allele Comparison: Met vs. Thr; Heterozygote Comparison: ThrMet vs. ThrThr; Homozygote Comparison: MetMet vs. ThrThr; Recessive Model: MetMet vs. ThrThr+ThrMet; Dominant Model: ThrMet+MetMet vs. ThrThr; P: p value for heterogeneity; Num: number of studies analyzed; NA: not available; * significant difference.